Skip to main content
PMHS
OTC Life Sciences

Polomar Converts $450,000 in Owed Commissions Into 10% Note Due March 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.125
Mkt Cap
$3.549M
52W Low
$0.065
52W High
$840,000
52W Position info
92% above low
Off High info
100% below high
Rel. Volume info
0.3× avg
Market data snapshot near publication time

PMHS sits 92% above its 52-week low of $0.065 on light trading volume (0.3× avg).

Summary

Polomar signed a $450,000 promissory note to Island 40 Group covering unpaid sales commissions. The note pays 10% interest through year-end and prime plus 4% after, maturing March 31, 2027, or earlier if the specialty pharmacy subsidiary is sold.


Key Events · Financing and Capital Events · PMHS

  • Commissions Converted to $450,000 Note

    Effective November 9, 2026, Polomar executed a Promissory Note and Loan Agreement with Island 40 Group, LLC for $450,000, reflecting commissions due under a Sales Director and Distribution Agreement.

  • Interest Steps Up After Year-End

    The note pays 10% simple interest through December 31, 2026, then the Wall Street Journal prime rate plus 4% until paid in full.

  • Maturity Tied to Pharmacy Sale

    Principal and interest are due March 31, 2027, or immediately upon closing the contemplated acquisition of Polomar Specialty Pharmacy, LLC, whichever is earlier.

  • Subsidiary Guarantees the Note

    Polomar Specialty Pharmacy, LLC is a party to the note as guarantor and accepts all obligations of the company.


Analysis · PMHS · Life Sciences

Rather than pay $450,000 in sales commissions owed to Island 40 Group in cash, Polomar signed a promissory note for that amount, guaranteed by its specialty pharmacy subsidiary. The debt carries 10% simple interest through December 31, 2026, then steps up to the Wall Street Journal prime rate plus 4%, and matures March 31, 2027 — or sooner if the company closes the sale of Polomar Specialty Pharmacy. For a company that has already flagged substantial doubt about continuing as a going concern, adding a $450,000 obligation with an acceleration trigger tied to a divestiture is a real balance-sheet constraint. The waiver of setoff and counterclaim rights further removes most of the company's defenses if a dispute arises.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PMHS was trading at $0.13 on OTC in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.07 to $840,000.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PMHS - Latest Insights

PMHS
Nov 03, 2026, 4:41 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.1875
Real-time Price: $0.12504 info
Change: -$0.06246 (-33%) info
Market Cap: $3.549M info
PMHS
Oct 19, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.120
Real-time Price: $0.12504 info
Change: +$0.00504 (+4%) info
Market Cap: $3.549M info
PMHS
Aug 14, 2026, 4:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.140
Real-time Price: $0.12504 info
Change: -$0.01496 (-11%) info
Market Cap: $3.549M info
PMHS
Jul 17, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.118
Real-time Price: $0.12504 info
Change: +$0.00704 (+6%) info
Market Cap: $3.549M info
PMHS
Jul 06, 2026, 4:38 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.118
Real-time Price: $0.12504 info
Change: +$0.00704 (+6%) info
Market Cap: $3.549M info